High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing
▪ Already 14 customer fills completed in the first quarter of 2023
▪ More than ten successfully completed customer audits confirm high quality and process standards
▪ Vetter underpins commitment to customers in drug development with expansion
Ravensburg, Germany, Rankweil, Austria, 09 May 2023 – Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), continues to drive the expansion of capacities and services for the provision of clinical trial materials: With the implementation of additional equipment for aseptic production and the expansion of storage capacities at the clinical site in Rankweil, Austria, the company is responding to increasing market demand. By the end of 2021, Vetter’s production in Rankweil was up and running, and 17 customer projects have already been won.
Dynamic development of the Rankweil location
Vetter has completed the first year of production in Rankweil successfully and is preparing to further increase production capacities and capabilities on site. With 14 batches already filled in the first quarter of 2023, the number of batches produced in total at the site in 2022 has already been surpassed. The further expansion of the site will make it possible to more than double the production volume by the end of the year.
The use of a second autoclave and washing machine for material preparation will significantly increase cleanroom utilization. Furthermore, the pharmaceutical service provider has doubled the capacity for cold storage by purchasing additional freezers. Vetter is also expanding its customer-oriented service offering – with the implementation of an isolator, powdered substances can now also be processed in Rankweil. Further options for primary packaging materials expand the portfolio for clinical filling.
Dr Claus Feussner, Senior Vice President, Vetter Development Service, is very satisfied: "In addition to our existing clinical manufacturing facility in Chicago, Rankweil has established itself in a very short time as a strategically important location for us and our partners. Customer service, efficient processes and our high quality standard are the focus.”
Find the Vetter press kit and more background information here.
Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than 6,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early-stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at https://www.vetter-pharma.com.
Vetter Pharma International GmbH
Corporate Spokesperson / Media Relations
Phone: +49 (0)751-3700-3729
E-mail: [email protected]
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape.
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer.
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shellThe latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin.
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
News Pfizer and Thermo Fisher Scientific partner to bring accessible NGS-based testing to international marketsThe collaboration between the pharmaceutical giant and scientific technology provider will aim to bring rapid and localised services to areas around the globe that lack affordable advanced genomic testing for breast and lung cancer.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance